Filing Details

Accession Number:
0001140361-16-075492
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-08-09 17:01:55
Reporting Period:
2016-08-08
Filing Date:
2016-08-09
Accepted Time:
2016-08-09 17:01:55
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
874716 Idexx Laboratories Inc IDXX In Vitro & In Vivo Diagnostic Substances (2835) 010393723
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1377232 Phd J Michael Williams One Idexx Drive
Westbrook ME 04092
Executive Vice President No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2016-08-08 21,432 $38.80 63,399 No 4 M Direct
Common Stock Disposition 2016-08-08 21,432 $108.92 41,967 No 4 S Direct
Common Stock Acquisiton 2016-08-08 42,698 $38.49 84,665 No 4 M Direct
Common Stock Disposition 2016-08-08 28,128 $108.96 56,537 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Non-Qualified Stock Option (right-to-buy) Disposition 2016-08-08 21,432 $0.00 21,432 $38.80
Common Stock Non-Qualified Stock Option (right-to-buy) Disposition 2016-08-08 42,698 $0.00 42,698 $38.49
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2018-02-13 No 4 M Direct
0 2018-05-31 No 4 M Direct
Footnotes
  1. Includes 76 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on June 30, 2016.
  2. Represents the weighted average sales price of the shares sold ranging from a low of $108.53 to a high of $109.29 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
  3. Represents the weighted average sales price of the shares sold ranging from a low of $108.56 to a high of $109.33 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
  4. Grant of option to buy 10,716 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five annual installments beginning on February 14, 2012, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
  5. Grant of option to buy 21,439 shares of IDEXX Laboratories, Inc. common stock that became exercisable five annual installments beginning on June 1, 2012, without giving effect to the Stock Split. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
  6. Not applicable.